Great review. Anyone looking for a detailed descri
Post# of 72447
(Total Views: 799)
Posted On: 05/10/2021 6:58:03 PM
Great review. Anyone looking for a detailed description of Remdesivir and Covid19 should also read the following article:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202249/
One of the reasons the information in the article is important is because Brilacidin has a chance of being the only antiviral which can lower mortality and complications of Covid 19.
If that proves true then it will follow the same course to approval as Remdesivir:
1. It will quickly be granted expanded compassion use {as well as the cash flow that will supply}.
2. Multiple accelerated phase 3 studies with funding
3. An EUA should be granted months before the phase 3 is studies are complete.
At that point the similarity to Remdesivir will end. IPIX will receive partnership offers.
Even though the volume of Covid19 cases is declining in the US.It is obvious the vaccine will not eliminate all of the cases.It will take years to vaccinate the whole world; if that is even feasible . It will also take years to understand how well the vaccine works, what are its side effects and how effective it is against mutations/variants.
If Brilacidin is proven to be effective against Covid19, Brilacidin will be stocked in every hospital pharmacy in the world. The Defense Department will need large stores for localized outbreaks of Covid19 eg ships, bases etc.In addition countries around the world will demand a supply.
At this point we just have to wait the outcome of the phase 2 study.
GLTA ,Farrell
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202249/
One of the reasons the information in the article is important is because Brilacidin has a chance of being the only antiviral which can lower mortality and complications of Covid 19.
If that proves true then it will follow the same course to approval as Remdesivir:
1. It will quickly be granted expanded compassion use {as well as the cash flow that will supply}.
2. Multiple accelerated phase 3 studies with funding
3. An EUA should be granted months before the phase 3 is studies are complete.
At that point the similarity to Remdesivir will end. IPIX will receive partnership offers.
Even though the volume of Covid19 cases is declining in the US.It is obvious the vaccine will not eliminate all of the cases.It will take years to vaccinate the whole world; if that is even feasible . It will also take years to understand how well the vaccine works, what are its side effects and how effective it is against mutations/variants.
If Brilacidin is proven to be effective against Covid19, Brilacidin will be stocked in every hospital pharmacy in the world. The Defense Department will need large stores for localized outbreaks of Covid19 eg ships, bases etc.In addition countries around the world will demand a supply.
At this point we just have to wait the outcome of the phase 2 study.
GLTA ,Farrell
(15)
(0)